Metagenomi director Laurence Reid buys $23,401 in company stock By Investing.com

Laurence Reid, a director at Metagenomi Therapeutics, Inc. (), recently acquired shares of the company’s common stock totaling $23,401. The transactions occurred on September 9, 2026.

Mr. Reid purchased a total of 20,000 shares of common stock. These shares were acquired at prices ranging from $1.17 to $1.18 per share. Specifically, 19,883 shares were acquired at a weighted average price of $1.17, and an additional 117 shares were purchased at $1.18 each. The purchase comes as MGX trades near its 52-week low of $1.13, down 37.6% over the past year from its 52-week high of $3.95.

Following these transactions, Mr. Reid directly holds 20,000 shares of Metagenomi Therapeutics common stock. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value calculation, placing it among companies on the most undervalued list. InvestingPro offers 11 additional exclusive tips for MGX investors seeking deeper analysis.

In other recent news, Metagenomi Inc reported its second-quarter 2026 financial results, revealing a net loss per share of $0.73, which did not meet the consensus estimate of $0.55. This larger-than-expected loss was attributed to a $2.6 million non-cash adjustment related to its collaboration with Ionis and higher research and development expenses. Wells Fargo responded by lowering its price target for Metagenomi shares from $9.00 to $7.00, although it maintained an Overweight rating on the stock. In another development, Chardan initiated coverage of Metagenomi with a buy rating and set a price target of $5.00. This rating is based on the potential of Metagenomi’s lead asset, MGX-001, as a one-time treatment for Hemophilia A. The firm transferred coverage to analyst Keay Nakae, who continues to hold a positive view on the company’s prospects. These recent developments provide insights into the company’s financial performance and future potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.